Metabolism plays an essential role in shaping T helper (Th) cell responses including the production of pro-inflammatory cytokines, however the effects on IL-10 have not been investigated. We show that the glucose analogue 2-deoxyglucose (2DG) specifically inhibits Th1 and Th2 cell differentiation and accompanying IL-10 production. In contrast, 2DG promotes IL-17A production by Th17 cells, even in the presence of IL-2 known to limit Th17 differentiation, whilst totally abrogating the production of IL-10. Notably, rather than inhibiting glycolysis, 2DG acts through the inhibition of glycosylation, which is critical for IL-2Ra surface expression and downstream signaling in both mouse and man. Strikingly, IL-2 is essential for IL-10 production by Th17 cells, in contrast to its inhibitory effect on the production of IL-17A. Our study reveals a previously unappreciated, antiinflammatory role for IL-2 in Th17 cell production of IL-10 and thus identifies a novel mechanism to limit Th17 pathogenicity.
INTRODUCTION
A balanced immune response is required to protect the host from pathogenic microorganisms without causing damage. Critical for this host defence are CD4 + T cells, which differentiate into effector T helper (Th)1, Th2, or Th17 cells with distinct cytokine profiles and functions (Zhu et al., 2010) . The individual Th cell fates are determined by the specific cytokine milieu in the local environment during T cell activation and downstream cytokine receptor signaling facilitated by signal transducer and activator of transcription (STAT) transcription factors: interleukin (IL)-12/STAT4 -Th1, IL-4/STAT6 -Th2 and IL-6/STAT3 and TGFb -Th17. The Th1, Th2 and Th17 cell identities and hallmark IFNg, IL-4 and IL-17A cytokine production are subsequently controlled by induction of the subset-specific hallmark transcription factor Tbet, Gata3 and Rorgt, respectively (Zhu et al., 2010) . Differentiated effector Th cells are each responsible for the clearance of a different class of pathogens, however, they can cause immunopathology unless restrained by anti-inflammatory mechanisms. These include CD4 + Foxp3 + regulatory T (Treg) cells (Maloy and Powrie, 2001) , T cell intrinsic molecules such as CTLA-4 or PD-1 (PentchevaHoang et al., 2009), or their own production of IL-10, which can dampen both innate and adaptive immune responses. Despite the above differences in their differentiation programs, all
Th cell subsets can produce IL-10 alongside their hallmark pro-inflammatory cytokines (Saraiva and O'Garra, 2010) . However, the specific factors that determine IL-10 production by the different Th cell subsets are unclear (Gabrysova et al., 2014) .
Metabolism has recently been shown to be critical in the shaping of Th cell responses.
CD4
+ T cell subsets preferentially utilize different metabolic pathways to direct their specification and support their function (MacIver et al., 2013; Pearce et al., 2013) . The differentiation from naïve to effector Th cells is associated with increased anabolic activity required for cell growth and proliferation, and is therefore subject to metabolic regulation. Whilst oxidative phosphorylation promotes Treg cells, differentiating Th effector cells have a greater dependence on glycolysis due to changes in their metabolic requirements (Delgoffe et al., 2009; Michalek et al., 2011; Shi et al., 2011) . Additionally, mediators of metabolic pathways activated upon antigen recognition have been shown to contribute directly to Th cell differentiation, preferentially targeting a given type of response. For example, the mechanistic target of rapamycin (mTOR) kinase, a metabolic sensor that controls protein synthesis, not only acts as the metabolic checkpoint for Th versus Treg cell differentiation (Delgoffe et al., 2009 ) but also specifically affects Th cell differentiation with mTORC1 and mTORC2 regulating Th1/Th17
and Th2 cell development respectively (Delgoffe et al., 2011) . Similarly, hypoxia-inducible factor 1a a , a regulator of glycolytic pathway enzymes induced downstream of mTOR, contributes to fate determination between Treg and Th17 cells, either through its effect on glycolysis (Shi et al., 2011) or through direct transcriptional activation of Rorc and Il17a whilst concurrently targeting Foxp3 for degradation (Dang et al., 2011) . The glycolysis associated enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) restricts Th1
responses by binding to the 3' untranslated region AU-rich elements of Ifng mRNA thus limiting its translation . However, the contribution of metabolism to Th cell proinflammatory hallmark cytokine production versus that of IL-10 is not known.
In this study, we use the glucose analogue 2-deoxyglucose (2DG) to restrict metabolic pathways during Th cell differentiation. We report that 2DG specifically inhibits Th1 and Th2 cell differentiation but promotes Th17 differentiation, which is accompanied by a concurrent inhibition of IL-10 production by all Th cell subsets. We demonstrate that 2DG can modulate Th cell responses through its effect on glycosylation of the IL-2Ra, rather than glycolysis.
Specifically, inhibition of IL-2Ra expression by 2DG during Th17 cell differentiation promotes IL-17A but blocks IL-10 production via its effects on IL-2 signaling. We further show that IL-2 is essential for IL-10 production by Th17 cells, contrary to its known inhibitory effect on the production of IL-17A, and also for increasing the responsiveness to IL-10 through the upregulation of Il10rb expression.
RESULTS

2DG affects Th cell differentiation and IL-10 production
To determine whether metabolism may contribute to the induction of an anti-inflammatory environment by effects on IL-10, and specifically whether glycolysis may differentially regulate Th cell IL-10 versus hallmark pro-inflammatory cytokine production, we cultured naïve mouse CD4 + T cells under Th1, Th2 and Th17 conditions in the presence of 2DG, a prototypical glycolytic pathway inhibitor ( Figure 1A) . Treatment of T cells with 2DG at an optimal 2DG/glucose ratio that had no effect on T cell recovery ( Figure S1 ) but specifically inhibited Gata3 in addition to Ifng and Il4, respectively, as well as Il10 ( Figure 1C) . Conversely, the expression of Rorc, the hallmark Th17 transcription factor, and Il17a was increased, but Il10 expression was downregulated by 2DG in T cells differentiated under Th17 conditions ( Figure   1C ). Thus, in the presence of 2DG IL-10 production was decreased in all Th cell subsets, indicating that whilst IL-10 produced by Th1 and Th2 cells is associated with their differentiation, fully differentiated Th17 cells do not produce IL-10.
2DG promotes Th17 cell differentiation even in the presence of IL-2
To further explore the mechanism of 2DG action on Th17 cells, and their production of IL-10, naïve T cells were labeled with CellTrace Violet and differentiated under Th17 conditions. At the highest concentration of 2DG (25 mM, where [glucose]:[2DG] = 1:1), the cells failed to proliferate (Figure 2A) . However, proliferation and T cell recovery were evident at 5 -10 mM 2DG and lower concentrations (Figure 2A and Figure S1 ). With respect to cytokine production, addition of increasing amounts of 2DG resulted in a reciprocal, dose-dependent increase in the frequency of IL-17A and decrease in IL-10-producing T cells (Figures 2A and 2B) . Strikingly, the percentage of IL-2-secreting T cells was also increased with higher concentrations of 2DG
( Figure 2B ). These results were further confirmed by corresponding levels of cytokines detected in the culture supernatants ( Figure 2C) and at the mRNA level ( Figure 1C and Figure 2D ). In contrast, Foxp3 levels under the Th17 polarizing conditions remained low throughout the 2DG titration ( Figure 2B ).
Since an inhibitory role for 2DG in Th17 differentiation has previously been reported using Click's medium (Shi et al., 2011) , we performed the above experiments using media other than IMDM as different media can affect Th17 differentiation (Veldhoen et al., 2009 ). However, similar results including, increased IL-17A and IL-2 but decreased IL-10 were also observed when Click's or RPMI culture media were used, which support lower levels of Th17 differentiation ( Figure S2A-D) . Although there was a shift in the 2DG dose response curve in Click's or RPMI medium as compared to the IMDM, this may be related to the amount of glucose present in the different media (5 mM, 10 mM and 25 mM, respectively) altering the 2DG/glucose ratio. We further investigated the possibility that the lower amount of anti-CD28 co-stimulation used in the Shi et al. study could explain the difference observed. However, as shown in Figure   S2E , 2DG promoted IL-17 production at both 10 µg/ml (this study) and 2 µg/ml (Shi et al., 2011) of anti-CD28, though again with a shifted dose response curve and a lower maximal induction of IL-17A (20% compared to 60% IL-17-producing cells, respectively). Thus, 2DG at optimal doses promoted Th17 differentiation and blocked IL-10 production regardless of culture media, amount of co-stimulation, or presence of high concentrations of IL-2.
2DG inhibits IL-2Ra expression and downstream IL-2 signaling
The fact that 2DG promoted Th17 differentiation in the presence of IL-2 was surprising since previous reports have shown that IL-2 blocks Th17 differentiation (Laurence et al., 2007; Yang et al., 2011) . We therefore hypothesized that the observed increase in IL-17A production could be due to a defect in IL-2 signaling. To address this, we measured the extent of STAT5 phosphorylation and found that it was indeed decreased in the presence of 2DG in comparison to the vehicle control ( Figure 3A) . We next examined the expression of upstream IL-2Ra (CD25). As shown in Figure 3B , IL-2Ra surface expression on T cells cultured under Th17
conditions was reduced by 2DG in a dose-dependent manner. However, 2DG did not have an effect on the expression of Il2ra mRNA ( Figure 3C ), indicating that the defect in IL-2Ra
expression was due to a block at the protein level rather than at the level of transcription. Of note, the effect of 2DG on IL-2Ra expression was also evident in T cells differentiated under Th1 and Th2 conditions ( Figure S3 ). In order to investigate whether 2DG also modulates IL2Ra expression in human CD4 + T cells, we obtained naïve and memory T cells from human PBMCs and cultured them under the same Th17 polarizing conditions. As shown in Figures 3D and E, 2DG treatment of human CD4 + T cells also resulted in decreased surface expression of IL-2Ra in both naïve and memory T cells, despite the higher mean fluorescence intensity of IL2Ra in memory T cells.
2DG acts to inhibit glycosylation rather than glycolysis to prevent IL-2Ra expression
In order to elucidate the metabolic mechanism of 2DG action on Th17 differentiation, we performed U-13 C-glucose labeling experiments. We differentiated naïve CD4 + T cells under However, label incorporation into mannose was greatly reduced in the presence of 2DG ( Figure   S4B ). This was not due to a lower rate of mannose synthesis but rather an increased total intracellular pool of mannose, with the amount of newly-synthesized glucose-derived mannose being the same in the presence or absence of 2DG ( Figure 4B ).
This observation was of interest since a known effect of 2DG is the inhibition of N-linked glycosylation ( Figure 4C ) resulting from the close resemblance of 2DG to mannose in addition to glucose (Kurtoglu et al., 2007) . Therefore, we next explored the possibility that 2DG at a concentration that blocks IL-2 signaling prevents IL-2Ra glycoprotein (Leonard et al., 1983) from being correctly glycosylated and transported to the cell surface. Supplementation of 4 mM mannose to Th17 cultures, which competes with native sugars and 2DG for glycosylation, resulted in an increase in IL-2Ra surface expression under optimal 2DG conditions when compared to the vehicle control ( Figure 4D) . Consequently, the phosphorylation of STAT5 was also increased ( Figure 4E ). These results indicate that 2DG influences the glycosylation of IL2Ra since its surface expression and downstream signaling can be restored by the addition of exogenous mannose. In order to confirm this, we performed Western blot analysis on Th17 cells differentiated in the presence or absence of 2DG and/or mannose. Peptide-N-Glycosidase F (PNGaseF) digestion revealed that IL-2Ra is glycosylated when cells are cultured under control conditions ( Figure 4F ). Glycosylation was not affected by addition of mannose alone to the culture medium ( Figure 4F ). In the presence of 2DG, however, the smaller amount of IL-2Ra detectable was mostly in the non-N-glycosylated form (shown here for clarity on a gel where total protein concentrations have been adjusted to similar IL-2Ra intensities; a gel with equally loaded total protein concentrations is shown in Figure S5 ), and this was overcome by the addition of exogenous mannose ( Figure 4F ). These results demonstrate that the observed effects of 2DG are predominantly due to inhibition of glycosylation, rather than glycolysis. We next sought to confirm these findings using Tunicamycin, a direct inhibitor of N-linked glycosylation that specifically inhibits the action of N-acetylglucosamine transferases, thus preventing glycosylation of newly-synthesized glycoproteins. Tunicamycin also affected IL-2Ra surface expression on T cells from Th17 cultures in a dose-dependent manner ( Figure 4G ).
Reciprocal role of IL-2 in Th17 differentiation and IL-10 production and responsiveness
Having established that 2DG enhances Th17 differentiation while inhibiting IL-10 production 
DISCUSSION
Although metabolism and glycolysis have been shown to play a role in pro-inflammatory cytokine production and lineage specification of CD4 + T cell subsets, it is not known whether it can also affect their IL-10 production. Using 2DG as a tool to inhibit metabolic pathways, we
show that IL-10 is differentially regulated in Th1 and Th2 versus Th17 cells. Low doses of 2DG specifically inhibited Th1 and Th2 cell differentiation but enhanced Th17 differentiation. This was accompanied by a concurrent inhibition of IL-10 production by all Th cell subsets. By exploring the mechanism of 2DG action, we show that 2DG promotes Th17 differentiation even in the presence of IL-2 as a result of its inhibitory effect on the surface expression of IL-2Ra
and downstream phosphorylation of STAT5. Strikingly, we further demonstrate that the mechanism of 2DG action is through the inhibition of glycosylation rather than glycolysis, which is critically important for the surface expression of IL-2Ra following T cell activation.
Low levels of phosphorylated STAT5 downstream of IL-2 signaling have been shown to be required for T cell proliferation and survival (Moriggl et al., 1999) . There are fundamental differences, however, between Th1 and Th2 versus Th17 cell in their dependency on IL-2 signaling for their differentiation. Whilst Th1 and Th2 cells are highly dependent on IL-2 (Cote- Sierra et al., 2004; Liao et al., 2011; Liao et al., 2008; Moriggl et al., 1999; Shi et al., 2008; Zhu et al., 2003) , Th17 differentiation is inhibited by IL-2 signaling (Laurence et al., 2007; . During Th1 differentiation, STAT5 is involved in inducing Tbx21 and Il12rb2 expression (Liao et al., 2011) and acts as a pioneer factor responsible for the opening of the Ifng locus (Shi et al., 2008) . Strong STAT5 signaling is also essential for maintaining the accessibility of the Il4 locus (Cote-Sierra et al., 2004; Zhu et al., 2003) and upregulation of Il4ra expression during Th2 differentiation (Liao et al., 2008) . In differentiating Th17 cells, on the other hand, STAT5 competes with STAT3 for binding to the Il17a gene locus and thus inhibits its expression . Consistent with the above effects of IL-2 on Th cell proliferation and differentiation, our data show that at high 2DG doses when IL-2Ra expression was completely abrogated, Th1, Th2 and Th17 cells were unable to divide. Whilst 2DG doses that permit low levels of IL-2Ra surface expression and lower levels of STAT5 phosphorylation no longer affected Th1 and Th2 cell expansion, their differentiation and accompanying cytokine production continued to be inhibited. IL-10 production was also inhibited suggesting that its production is tightly linked to the differentiation program of Th1 and Th2 cells. IL-10 has previously been shown to be produced by Th17 cells differentiated in vitro with IL-6 and TGFb (Gagliani et al., 2015; McGeachy et al., 2007) , which were also shown to restrain Th17-cell mediated pathology (Gagliani et al., 2015; Ghoreschi et al., 2010; McGeachy et al., 2007) . Recently, others have reported Th17 cells to be heterogeneous with respect to IL-10 versus pro-inflammatory cytokine production (Gaublomme et al., 2015) . Our results demonstrate that IL-2 is the critical factor in determining IL-10 production by Th17 cells differentiated in the presence of IL-6 and TGFb. However, this is likely held in delicate balance since low levels of IL-2 are required for T cell proliferation and survival (Moriggl et al., 1999) , whereas high levels of IL-2 induce IL-10 but concurrently inhibit their IL-17 production.
Therefore, in conditions favoring Th17 and not Th1 or Th2 differentiation, the major factor that maintains immune regulation and inhibits Th17-mediated pathology is IL-2, which we now show will favor IL-10 production by Th17 themselves. Importantly, this is not associated with a conversion to a more pathogenic phenotype expressing Tbet and IFNg despite the ability of IL-2 to promote Th1 responses. Moreover, we demonstrate that IL-2 also upregulates Th17 cell expression of Il10rb. IL-10 has previously been shown to act in both a paracrine manner, augmenting Treg-mediated suppression of Th17 cell activity and in an autocrine manner, providing an autofeedback loop to directly limit Th17 responses (Huber et al., 2011) . Therefore, IL-2 not only promotes Th17 cell production of IL-10, but also enhances their sensitivity to IL-10 and thus limits their pathogenicity.
The ability of IL-2 to induce Foxp3 + Treg cells is a well-known aspect of its antiinflammatory action and has been suggested to explain why the deletion of IL-2 or IL-2 receptor in mice results in the development of autoimmunity (Hoyer et al., 2008) . Correspondingly, humans with inherited deficiencies in the IL-2 receptor or STAT5 suffer from autoimmune disease (Malek et al., 2008) . Low dose IL-2 therapy has already been shown to be efficacious in the control of autoimmune and inflammatory diseases through its effect on Foxp3 + Treg cells (Koreth et al., 2011; Saadoun et al., 2011) . Our study additionally reveals that the ability of IL-2 to inhibit Th17 differentiation and promote the production of IL-10 by Th17 cells may also be relevant. However, the effect of IL-2 on IL-10 in the above settings has not been explored and warrants further investigation. Indeed, a human case study linking IL-2Ra deficiency to loss of IL-10 production further supports the rationale (Caudy et al., 2007) .
Here we report that glycosylation limits Th17 cell differentiation but promotes IL-10 production via modulation of the IL-2 signaling axis through its effect on the surface expression of IL-2Ra. Therefore, in addition to IL-2 promoting an anti-inflammatory environment through the induction of Foxp3 + Treg cells, our studies reveal a novel, previously unappreciated role for IL-2 to limit Th17 cell pathogenicity by inducing IL-10 production in Th17 cells. Our results further indicate that modulation of IL-2 signaling, be it direct or through glycosylation, may be exploited as a therapeutic target for the treatment of T cell-mediated inflammatory diseases.
EXPERIMENTAL PROCEDURES
Animals.
C57BL/6 mice were bred and maintained under specific pathogen-free conditions at The Francis Crick Institute, Mill Hill laboratory according to the Home Office UK Animals (Scientific Procedures) Act 1986 and used at 8-12 weeks of age.
Naïve T cell sorting and in vitro differentiation.
Naïve CD4 + CD62L + CD44 lo CD25 -T cells were purified to >98% from CD4-enriched spleens by negative selection and further by sorting on a MoFlo TM XDP cytometer (Beckman Coulter).
Sorted T cells were cultured in either IMDM (5 or 10% FCS, 1 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 0.05 mM b-2-mercaptoethanol), RPMI (10% FCS, 1 mM glutamine, 10 mM HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin, 1mM sodium pyruvate and 0.05 mM b-2-mercaptoethanol (Gibco)) or Click's media (10% FCS, 1 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 0.05 mM b-2-mercaptoethanol) at 5 × 10 5 per well in flat-bottom 48-well plates in a total volume of 1 ml complete media and cultured for up to 7 days as indicated. For Th1 differentiation, naïve T cells were activated with plate-bound anti-CD3 (5 µg/ml, 145-2C11, Harlan) and soluble anti-CD28 (2 µg/ml, 37.51, Harlan) in the presence of recombinant mIL-12p70 (5 ng/ml, Biolegend) and anti-IL-4 (10 µg/ml, 11.B.11, gift from DNAX). For Th2 differentiation, naïve T cells were activated as above in the presence of recombinant mouse IL-4 (10 ng/ml; R&D Systems), IL-2 (5 ng/ml; Insight Biotechnology), anti-IL-12p40 (10 µg/ml, C17.8.20, gift from DNAX) and anti-IFNg (10 µg/ml, XMG1.2, Harlan).
For Th17 differentiation, naïve T cells were activated with plate-bound anti-CD3 (2 µg/ml) and anti-CD28 (10 µg/ml, or 2 µg/ml where indicated) in the presence of recombinant human TGFb1
(2 ng/ml, R&D Systems), human IL-6 (50 ng/ml, R&D Systems) and anti-IFNg, anti-IL-4 and anti-IL-12p40 (all at 10 µg/ml), for certain experiments IL-2 (1, 5 or 10 ng/ml) or anti-IL-2 (0.1, 1 or 10 µg/ml, JES6 1A12, gift from DNAX) were added as indicated. For pharmacological inhibitor treatments, cells were treated with 0.25-25 mM 2DG (Sigma-Aldrich) or vehicle control (H2O), or 62.5-400 ng/ml tunicamycin (Sigma-Aldrich) at the onset of cultures. Where indicated, 4 mM mannose (Sigma-Aldrich) was further added to the 2DG-containing cultures.
Flow cytometry, intracellular cytokine and phosphoprotein staining. 
Real-time PCR.
Total RNA was extracted using RNeasy Isolation Kit (Qiagen) and reverse transcribed into cDNA using as High Capacity Reverse Transcription kit (Applied Biosystems), according to manufacturer's instructions, followed by RNaseH (Promega) treatment for 30 min at 37°C.
cDNA was analyzed for the expression of transcription factors and cytokines by an ABI 7900HT
Fast PCR real-time system using the following TaqMan primer probes to mouse Tbx21,
Mm00484683_m1; Il4, Mm00445260_m1; Rorc, Mm01261019_g1 and Il17a,
Mm00439619_m1, all from Applied Biosystems. The comparative threshold cycle method with
Hrpt1, Mm00446968_m1 as an internal control was used for the normalization of target gene expression.
Cytokine quantification.
Secreted cytokines were measured in supernatants after 3 to 5 days of culture by an enzymelinked immunosorbent assay as previously described (Shoemaker et al., 2006) . IL-2 (capture JES6-1A12, detection JES6-5H4; both gifts from DNAX) and IL-10 (capture JES5-2A5, eBioscience; detection SXC-1, BD) were used followed by horseradish peroxidase-conjugated Streptavidin (Jackson mmunoResearch Laboratories Inc.) and developed with ABTS (SigmaAldrich) and TMB (eBioscience) substrates, respectively. IL-17A was quantified using commercially available ELISA kit (eBioscience) according to the manufacturer's instructions.
Stable isotope labeling and metabolite extraction of T cells.
Naïve CD4 Polar metabolite extracts were analysed by GC-MS (Agilent 7890B-5977A), as previously described (Saunders et al., 2011) . Identification, abundance and label incorporation of individual metabolites was estimated as previously described (MacRae et al., 2013) . To ensure that starting medium is consistent between experiments, aliquots (5 µL) were derivitized and analyzed by GC-MS (as above) for each sample.
Immunoblot analysis.
Naïve T cells were cultured for 2.5 days under Th17 polarizing conditions, after which cells were washed with PBS and lysed in RIPA lysis buffer (Kaiser et al., 2009) . Protein concentrations were quantified using Pierce BCA assay kit (ThermoFisher Scientific). For removal of oligosaccharides from N-linked glycoproteins, lysates were treated with PNGase F according to manufacturer's instructions (New England BioLabs Inc.). Both untreated and PNGase F treated T cell protein extracts were separated by 10% SDS-polyacrylamide gel and transferred to PVDF membranes (Millipore). Membranes were probed with primary antibodies to IL-2Ra (Novus Biologicals) and GAPDH (Santa Cruz Biotech) followed by horseradish peroxidase-conjugated goat anti-rabbit IgG (Southern Biotech) for detection of target proteins with Pierce ECL Western blotting substrate (ThermoFisher Scientific).
Human T cell cultures.
All work with human blood samples was approved by the ethical research committee of Guy's hospital under the permit number 14/LO/1699 and informed consent taken from all subjects.
Human PBMCs were obtained from healthy individuals and isolated using a Ficoll gradient as previously described (Richards et al., 2000) . For Th17 differentiation, 5 × 10 5 T cells per well in flat-bottom 48-well plates in a total volume of 1 ml complete IMDM media were activated with plate-bound anti-CD3 (2 µg/ml, OKT-3) and anti-CD28 (2 µg/ml, CLB-CD28/1, 15E8, Sanquin PeliCluster), and cultured for 5 days in the presence of recombinant human TGFb1 (2 ng/ml, R&D Systems), human IL-6 (50 ng/ml, R&D Systems) and anti-IFNg (B-B1; BioSource) and anti-IL-4 (MP4-25D2, BD) both at 10 µg/ml.
Expression of IL-2Ra was evaluated directly without restimulation by surface staining CD25
APC-H7 (M-A251, BD).
RNA-Seq
mRNA was prepared from 3 biological replicates of differentiated Th17 cells with added IL-2 (10 ng/ml) or anti-IL-2 (10 µg/ml) for three days followed by 4 h restimulation with PDBU and Ionomycin at 500 ng/ml each. Cells were stained for the surface protein CD4 and dead cells using e450 LIVE/DEAD fixable dead cell stain, fixed with 4% formaldehyde and live, CD4 + T cells were sorted on FACSAria cell sorter (BD Biosecinces) using FACSDiva software. Total RNA was isolated using the FFPE RNeasy Kit (Qiagen). Samples were poly-A purified and converted to cDNA libraries using the Illumina TruSeq Library preparation kit v2 and sequenced using the Illumina HiSeq 2000 platform with single-end read lengths of 50 bp to sequencing depth of between 27 × 10 6 to 65 × 10 6 reads per sample. Reads were aligned to the mouse transcriptome (GRCm38 / mm10, 2014.10.08) using Strand NGS (Version 2.0) guided by RefSeq annotations (2013.04.01), with 95% identity, max 5% gaps, 1 read only if duplicated.
Samples were normalised using the count based technique DeSeq. Differentially regulated genes were obtained by unpaired t-test, unequal variance (Welch) with Benjamini-Hochberg p < 0.05 multiple testing correction followed by further filtering on transcripts by fold change (FC) > 1.5.
Statistical analysis.
GraphPad Prism Version 6 was used to perform statistical analysis where indicated. The statistical significance of differences between data groups was determined by a Student's t-test or a two-way ANOVA (see individual figure legends) at the 95% confidence level. 
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